265 related articles for article (PubMed ID: 30557809)
1. Therapeutic blockade of the interleukin-6 receptor (IL-6R) allows sIL-6R generation by proteolytic cleavage.
Prenissl N; Lokau J; Rose-John S; Haybaeck J; Garbers C
Cytokine; 2019 Feb; 114():1-5. PubMed ID: 30557809
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor.
Garbers C; Thaiss W; Jones GW; Waetzig GH; Lorenzen I; Guilhot F; Lissilaa R; Ferlin WG; Grötzinger J; Jones SA; Rose-John S; Scheller J
J Biol Chem; 2011 Dec; 286(50):42959-70. PubMed ID: 21990364
[TBL] [Abstract][Full Text] [Related]
3. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.
Mihara M; Kasutani K; Okazaki M; Nakamura A; Kawai S; Sugimoto M; Matsumoto Y; Ohsugi Y
Int Immunopharmacol; 2005 Nov; 5(12):1731-40. PubMed ID: 16102523
[TBL] [Abstract][Full Text] [Related]
4. The balance of interleukin (IL)-6, IL-6·soluble IL-6 receptor (sIL-6R), and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and trans-signaling.
Baran P; Hansen S; Waetzig GH; Akbarzadeh M; Lamertz L; Huber HJ; Ahmadian MR; Moll JM; Scheller J
J Biol Chem; 2018 May; 293(18):6762-6775. PubMed ID: 29559558
[TBL] [Abstract][Full Text] [Related]
5. Function and proteolytic generation of the soluble interleukin-6 receptor in health and disease.
Schumertl T; Lokau J; Rose-John S; Garbers C
Biochim Biophys Acta Mol Cell Res; 2022 Jan; 1869(1):119143. PubMed ID: 34626681
[TBL] [Abstract][Full Text] [Related]
6. Cathepsin S provokes interleukin-6 (IL-6) trans-signaling through cleavage of the IL-6 receptor in vitro.
Flynn CM; Garbers Y; Düsterhöft S; Wichert R; Lokau J; Lehmann CHK; Dudziak D; Schröder B; Becker-Pauly C; Rose-John S; Aparicio-Siegmund S; Garbers C
Sci Rep; 2020 Dec; 10(1):21612. PubMed ID: 33303781
[TBL] [Abstract][Full Text] [Related]
7. The interleukin-6 receptor Asp358Ala single nucleotide polymorphism rs2228145 confers increased proteolytic conversion rates by ADAM proteases.
Garbers C; Monhasery N; Aparicio-Siegmund S; Lokau J; Baran P; Nowell MA; Jones SA; Rose-John S; Scheller J
Biochim Biophys Acta; 2014 Sep; 1842(9):1485-94. PubMed ID: 24878322
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-6: A Masterplayer in the Cytokine Network.
Uciechowski P; Dempke WCM
Oncology; 2020; 98(3):131-137. PubMed ID: 31958792
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-6 and its receptor: from bench to bedside.
Scheller J; Rose-John S
Med Microbiol Immunol; 2006 Dec; 195(4):173-83. PubMed ID: 16741736
[TBL] [Abstract][Full Text] [Related]
10. Activation of Toll-like Receptor 2 (TLR2) induces Interleukin-6 trans-signaling.
Flynn CM; Garbers Y; Lokau J; Wesch D; Schulte DM; Laudes M; Lieb W; Aparicio-Siegmund S; Garbers C
Sci Rep; 2019 May; 9(1):7306. PubMed ID: 31086276
[TBL] [Abstract][Full Text] [Related]
11. Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach.
Gibiansky L; Frey N
J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):5-16. PubMed ID: 22101760
[TBL] [Abstract][Full Text] [Related]
12. Minimal interleukin 6 (IL-6) receptor stalk composition for IL-6 receptor shedding and IL-6 classic signaling.
Baran P; Nitz R; Grötzinger J; Scheller J; Garbers C
J Biol Chem; 2013 May; 288(21):14756-68. PubMed ID: 23564454
[TBL] [Abstract][Full Text] [Related]
13. Proteolytic Origin of the Soluble Human IL-6R In Vivo and a Decisive Role of N-Glycosylation.
Riethmueller S; Somasundaram P; Ehlers JC; Hung CW; Flynn CM; Lokau J; Agthe M; Düsterhöft S; Zhu Y; Grötzinger J; Lorenzen I; Koudelka T; Yamamoto K; Pickhinke U; Wichert R; Becker-Pauly C; Rädisch M; Albrecht A; Hessefort M; Stahnke D; Unverzagt C; Rose-John S; Tholey A; Garbers C
PLoS Biol; 2017 Jan; 15(1):e2000080. PubMed ID: 28060820
[TBL] [Abstract][Full Text] [Related]
14. Enhancing Interleukin-6 and Interleukin-11 receptor cleavage.
Lokau J; Wandel M; Garbers C
Int J Biochem Cell Biol; 2017 Apr; 85():6-14. PubMed ID: 28143719
[TBL] [Abstract][Full Text] [Related]
15. Soluble interleukin-6 receptor (sIL-6R) makes IL-6R negative T cell line respond to IL-6; it inhibits TNF production.
Igaz P; Horváth A; Horváth B; Szalai C; Pállinger E; Rajnavölgyi E; Tóth S; Rose-John S; Falus A
Immunol Lett; 2000 Mar; 71(3):143-8. PubMed ID: 10722865
[TBL] [Abstract][Full Text] [Related]
16. Influence of humanized anti-IL-6R antibody, tocilizumab on the activity of soluble gp130, natural inhibitor of IL-6 signaling.
Hashizume M; Mihara M
Rheumatol Int; 2009 Feb; 29(4):397-401. PubMed ID: 18802703
[TBL] [Abstract][Full Text] [Related]
17. Tocilizumab does not block interleukin-6 (IL-6) signaling in murine cells.
Lokau J; Kleinegger F; Garbers Y; Waetzig GH; Grötzinger J; Rose-John S; Haybaeck J; Garbers C
PLoS One; 2020; 15(5):e0232612. PubMed ID: 32365119
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary.
Yanaihara N; Hirata Y; Yamaguchi N; Noguchi Y; Saito M; Nagata C; Takakura S; Yamada K; Okamoto A
Mol Carcinog; 2016 May; 55(5):832-41. PubMed ID: 25856562
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer.
Rose-John S; Scheller J; Elson G; Jones SA
J Leukoc Biol; 2006 Aug; 80(2):227-36. PubMed ID: 16707558
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease.
Nishimoto N; Terao K; Mima T; Nakahara H; Takagi N; Kakehi T
Blood; 2008 Nov; 112(10):3959-64. PubMed ID: 18784373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
